This Is Where AI Drug Deals Quietly Fall Apart.
The meeting was going well. The science was compelling. The team had answered every question about the mechanism, the preclinical data, the development pathway. Then the diligence team came back, not the scientific team, the technical and legal team and the conversation changed register entirely.
They weren’t asking about the molecule anymore. They were asking about training data provenance. About who owns the optimization workflow. About what happens to platform improvement rights when the current collaboration structure ends. About whether the model architecture has third-party dependencies that survive in a standalone acquisition.
The team didn’t have clean answers. Not because the answers were necessarily bad, but because no one had built the system to produce them. Three weeks later, the conversation had quietly lost its momentum.
This is how deals fall apart now. Not dramatically. Quietly.
Diligence Has Evolved. Most Companies Haven’t.
The framework for evaluating AI-enabled biotech assets has changed substantially over the past two years. The change has been driven by acquirers and institutional investors who have closed enough transactions in this space to understand where the structural risks actually live and who have, in some cases, paid for that understanding through deals that looked clean and weren’t.
The new diligence is not replacing the old diligence. Freedom to operate still matters. Chain of title still matters. Inventorship still matters. But sophisticated counterparties have added a layer of scrutiny that most companies’ preparation playbooks don’t cover yet: a systematic examination of the ownership and governance infrastructure surrounding the discovery process itself.
That includes how training data was sourced, licensed, and documented. It includes what rights the company retains when it improves a model trained on externally licensed inputs. It includes how IP flows, or doesn’t, through CRO relationships, computational collaborations, and cloud-based optimization services. It includes whether the company’s commercialization rights are as portable as the executive team believes them to be.
The Problems That Create the Most Friction Aren’t the Ones People Expect
There’s a version of AI diligence risk that gets a lot of attention: inventorship challenges, the question of whether AI-generated claims are valid, whether a competitor might challenge the patent on grounds related to AI’s role in the discovery. These are legitimate issues and they warrant attention.
But in practice, the issues that most frequently slow or derail transactions are more mundane and more structural. They are:
Assignment gaps — contributors to the discovery process whose IP wasn’t cleanly assigned, including contractors, academic collaborators, and employees who left before the paperwork was completed.
Data licensing ambiguity — external datasets whose commercialization terms were never mapped to the specific use case the company is now trying to monetize.
Collaboration scope creep — agreements whose IP provisions were drafted for a narrower scope of work than the relationship eventually covered.
Model provenance opacity — an inability to demonstrate clearly what went into building the platform, in a way that would survive an adversarial review.
Downstream improvement rights — uncertainty about who owns enhancements made to a platform in the context of a partnership that has since ended or is about to.
None of these are exotic. All of them are fixable but significantly harder to fix once a transaction is in motion and the cost of ambiguity is being priced in real time.
The Asymmetry
Identifying and resolving ownership gaps before a transaction costs a fraction of what it costs to negotiate around them during one, and a fraction of what it costs in valuation when an acquirer or investor decides to price the uncertainty rather than wait for resolution.
Transaction Readiness Is Not the Same as Deal Preparation
There is a distinction worth drawing carefully. Deal preparation is what companies do when a specific transaction is approaching, building the data room, preparing management presentations, briefing counsel on the deal-specific issues. It is inherently reactive, and for AI-enabled companies, it is increasingly insufficient.
Transaction readiness is different. It is the ongoing discipline of maintaining ownership infrastructure in a state that can withstand serious scrutiny at any moment, not because a deal is imminent, but because that state of readiness is itself strategically valuable. It determines who you can partner with, how quickly you can close, and how much negotiating leverage you carry into any commercial conversation.
The companies with the cleanest IP infrastructure in this space have a material advantage that shows up well before any deal is on the table. They can engage with potential partners from a position of genuine confidence. They don’t lose weeks to diligence remediation. They don’t have conversations that start strong and gradually lose altitude as reviewers find the gaps that should have been addressed two years earlier.
“The biggest transaction risks in AI therapeutics are rarely visible in the patent claims. They live in the systems, agreements, workflows, and assumptions that were built around the discovery process, and their cost is highest when someone else finds them first.”
What the Next Generation of Diligence Demands
Counterparties evaluating AI-enabled biotech assets are increasingly asking a question that sits underneath all the standard diligence questions: is this platform what it appears to be? Not scientifically, the science can be validated. But structurally. Does the company actually control what it thinks it controls? Can the asset be acquired, licensed, or partnered in the way the company is representing it can?
Answering that question cleanly requires having built the infrastructure to answer it, not assembled the documentation hastily when the question arrived. The companies that have done that work carry it as a durable advantage. The companies that haven’t tend to discover the gap at exactly the moment they can least afford to.
Deals don’t fall apart dramatically. They lose momentum. They get repriced. They close at terms that reflect uncertainty rather than strength. Usually by the time a company understands what happened, the conversation has already moved on.
The work that prevents that outcome isn’t done in the deal room. It’s done years before anyone sits down at the table.